DRUG
Bright Minds Biosciences Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
—
Largest filed tie
13F top-10 QoQ
Top fund weight
Bright Minds Biosciences has 11 disclosed suppliers and 0 disclosed customers in SEC filings.
Bright Minds Biosciences Inc.
54.98
Expected move
No implied move.
SentenceAlzheimer's Disease Dave Morgan Test the compound for behavioral changes in APP+PS1 mice (model of Alzheimer's Disease) Test compound showed significant effect in agitation in open field without other effects on learning and memory performance
DRUG 20-Faccession 0001062993-24-021301
SentenceOpioid withdrawal (Opioid use disorder, OUD) Substance use Disorder in rats (Dr. Cunningham lab) Determine the efficacy of test compound to suppress drug intake in male rats trained to stably self-administer fentanyl Rats treated with test compound (in higher doses) experienced 65% less fentanyl intake in an opioid use rat model
DRUG 20-Faccession 0001062993-24-021301
SentenceSafety Screen 44, hERG screening and Ames test at Eurofins (both 2A and 2A/2C programs)
DRUG 20-Faccession 0001062993-24-021301
SentenceThe Company leases its executive headquarters located at 19 Vestry St., New York, NY 10013 pursuant to a lease agreement (the " Vestry Lease Agreement ")between the Company and Gerep Realty Corp., as landlord, dated August 13, 2021, as amended on May 31, 2022.
DRUG 20-Faccession 0001062993-24-021301
SentenceHead Twitch Response trials (Halberstadt lab) (both 2A and 2A/2C programs) Evaluate head twitch response in mice 16 BMB compounds screened with a range of activity in vivo. The most active compounds are selected for a further assessment in ADMEPK studies
DRUG 20-Faccession 0001062993-24-021301
SentenceLead optimization - BRET (Bioluminescence Resonance Energy Transfer) assays (John McCorvy) Describe the 5-HT2 profile of the test compounds Choose lead and backup compounds More than 100 compounds screened and profiled Lead and backup compounds with minimal 2B agonism are selected
DRUG 20-Faccession 0001062993-24-021301
SentenceEpilepsy NIH ETSP program (collaboration on epilepsy).
DRUG 20-Faccession 0001062993-24-021301
SentencePain Preclinical Screening Platform for Pain (PSPP) - NIH collaboration (plantar incision and L5/L6 nerve ligation rat models) In vitro opioid & abuse liability, PK and protein binding studies Assess effects in animal pain models The test compound has passed the Tier 1 and is in process of Tier 2 studies BMB-201 significantly reduced mechanical allodynia, but not guarding behavior, in a dose-dependent manner. In female rats, 30 mg/kg of A39a significantly reduced both mechanical allodynia and guarding behavior compared to vehicle-treated rats of the same sex. 10 mg/kg also had a modest effect on guarding behavior in females.
DRUG 20-Faccession 0001062993-24-021301
SentencePsychoGenics Inc. collaboration (SmartCube model) To assess the potential of compounds to treat psychiatric disorders by comparing their complex behavioral profiles with those from a proprietary reference database at the drug class level BMB compounds showed clear antidepressant class profile in SmartCube model
DRUG 20-Faccession 0001062993-24-021301
SentenceThe Company leases laboratory space located at Technology Innovation Center, 10437 W Innovation Dr, Wauwatosa, WI 53226 pursuant to a commercial laboratory lease dated May 10, 2021, as amended as of November 17, 2021, May 27, 2022, January 3, 2023, May 9, 2023, and May 6, 2024 (the " Wisconsin Lease ") between the Company and Technology Innovation Center LLC.
DRUG 20-Faccession 0001062993-24-021301
SentenceThe Company leases office space located at Portal Innovations, 400 N. Aberdeen St., Suite 900, Chicago, IL 60647 pursuant to a Chicago membership agreement (the " Chicago Agreement ") between the Company and ZoE Life Fulton Labs Incubator, LLC, with an initial date of November 28, 2023, as extended on December 3, 2024.
DRUG 20-Faccession 0001062993-24-021301
—
—
Largest filed tie
—